Sorrento Therapeutics Inc

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It operates through the Sorrento Therapeutics and Scilex segments. The Sorrento Therapeutics segment consists of developing a portfolio of next generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. The Scilex segment is largely organized around the company's non-opioid pain management operations. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

SAN DIEGO, June  12, 2020  (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it prepaid in full its outstanding term loans on June 12, 2020.

Sorrento Announces Full Repayment of Outstanding Term Loans

The company could receive regulatory approval for its coronavirus antibody test.

Why Sorrento Therapeutics Stock Is Up Today

Sorrento Therapeutics Inc (NASDAQ: SRNE) shares were headed higher Thursday following an announcement concerning its antibody test kit for SARS-CoV-2, the virus that causes COVID-19.

Sorrento Rallies On EUA Filing For Rapid COVID-19 Antibody Test Kit

SAN DIEGO, June  10, 2020  (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that an Application for Emergency Use Authorization (EUA) is under review at the U.S. Food and Drug Administration (FDA) for its COVI-TRACKTM in vitro diagnostic test kit for the independent detection of IgG and IgM antibodies in sera of patients exposed to the SARS-CoV-2 virus.

Sorrento Announces It Has Submitted an Emergency Use Authorization (EUA) Application for the COVI-TRACK Diagnostic Test for the Detection of Antibodies to SARS-CoV-2

The biotech's coronavirus programs are exciting. But it's still really early.

Sorrento Therapeutics Could Have a COVID-19 Cure: Is the Stock a Buy?

The drug blocked the SARS-CoV-2 virus from replicating in a preclinical experiment.

Sorrento Reports It Has a Second Potential Antidote for COVID-19

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) shares are trading higher after the company announced its STI-4398 demonstrated ability in preclinical studies to completely inhibit the Sars-Cov-2 viral infection in vitro.

Why Sorrento's Stock Is Trading Higher Today

SAN DIEGO, June 5, 2020 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced it has completed a preclinical batch of the STI-4398 (COVIDTRAP) protein and is reporting the positive results from preclinical testing of its ability to neutralize and inhibit...

Sorrento COVIDTRAP™(STI-4398) Demonstrates in Preclinical Studies its Ability to Completely Inhibit SARS-CoV-2 Viral Infection In Vitro

Aurinia Pharmaceuticals

Here's how one biotech company can make investors rich, and why another should be avoided.

Biotech Stocks: Buy This, Not That

Two factors appear to be behind Sorrento's stock decline.

Why Sorrento Therapeutics Shares Are Tumbling Today

SAN DIEGO, May 29, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has been filed on behalf of all those who purchased or otherwise, acquired Sorrento Therapeutics, Inc. ("Sorrento" or the "Company") (NASDAQ: SRNE) between May 15,...

(SRNE) Lead Plaintiff Alert: Does Your Loss Exceed $100,000 In Sorrento Therapeutics? Contact Johnson Fistel, LLP

Arcturus Therapeutics

Dynavax Technologies

iBio

Inovio Pharmaceuticals

Moderna

Novavax

A race to develop a coronavirus vaccine is on, and these red-hot Covid-19 vaccine stocks are leading the way.

7 Red-Hot Biotech Stocks Racing to Develop a Coronavirus Vaccine

NEW YORK, May 28, 2020 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Sorrento Therapeutics, Inc. ("Sorrento" or "the Company") (NASDAQ: SRNE) and certain of its officers, on behalf of...

SRNE Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Sorrento Therapeutics, Inc and Encourages Investors to Contact the Firm

SAN DIEGO, May 28, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by Sorrento Therapeutics, Inc. ("Sorrento" or the "Company") (NASDAQ: SRNE). On May 20, 2020, Hindenburg Research issued a report...

(SRNE) Alert: Johnson Fistel Investigates Sorrento Therapeutics; Investors Suffering Losses Encouraged to Contact Firm

Sorrento Therapeutics Inc's (NASDAQ: SRNE) coronavirus program has been met with equal optimism and skepticism, which has led to wild swings in its stock price.

Sorrento Therapeutics Has $4B Coronavirus Opportunity, Analyst Says

SAN DIEGO, May  26, 2020  (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced it has received clearance from the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) application for STI-6129, a CD38-targeting antibody drug conjugate (ADC). STI-6129 utilizes several technology platforms that are under development by Sorrento Therapeutics, including a CD38 specific antibody identified from its fully human G-MAB™ antibody library, its proprietary drug payload Duostatin 5 and its site-specific C-LOCK conjugation technology.

Sorrento Receives FDA IND Clearance to Initiate a Phase I Clinical Trial of its CD38 Antibody-Drug Conjugate (ADC) STI-6129 for Patients with Amyloidosis

Sorrento Therapeutics Inc (NASDAQ: SRNE) shares caught fire Friday after the company said it has discovered a coronavirus antibody that 100% inhibits the pathogen.

Short Sellers Challenge Sorrento's Announcement Of 100% Coronavirus Inhibition: 'Manipulative At The Worst Time'

Euphoria over the biotech's announcement last week continues to fade.

Why Sorrento Therapeutics Stock Is Sinking Again Today

Which stock wins in a match-up between these two high-flying biotechs with promising COVID-19 programs?

Better Coronavirus Stock:  Moderna vs.  Sorrento Therapeutics

Here's Why Sorrento Therapeutics Dropped 16.6% Today

The biotech's experimental antibody holds the potential to neutralize the novel coronavirus that causes COVID-19. Time to buy Sorrento?

Is Sorrento Therapeutics Stock a Buy After Its Promising Coronavirus News?

Sorrento Therapeutics Inc (NASDAQ: SRNE) shares spiked 158% Friday after the company disclosed that it has identified an antibody that demonstrated 100% inhibition of SARS-CoV-2 virus infection.

Sorrento Therapeutics Analyst Says Coronavirus Antibody Cocktail One Of Few Non-Vaccine Options

Sorrento Therapeutics says it’s made a major breakthrough in a temporary, preventative treatment for COVID-19, which could help bridge the gap until a vaccine is available.

This biotech company says its coronavirus antibody treatment blocked 100% of infections in lab tests

Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares jumped to start the week after the company announced that its COVID-19 antibody treatment had a positive showing.

Why Sorrento Therapeutic’s Antibody Breakthrough Is Huge

Sorrento's shares are continuing their surge from last Friday. Here's why.

News for Sorrento Therapeutics Inc Stock (SRNE)